首页 | 本学科首页   官方微博 | 高级检索  
检索        

阿托伐他汀对慢性心力衰竭患者血浆骨桥蛋白的影响
引用本文:沈桂彬,张丽华.阿托伐他汀对慢性心力衰竭患者血浆骨桥蛋白的影响[J].中国综合临床,2014(4):376-378.
作者姓名:沈桂彬  张丽华
作者单位:[1]河南省郑州市第七人民医院心内科,450016 [2]郑州大学第二附属医院心内科,450016
摘    要:目的 观察阿托伐他汀对慢性心力衰竭(CHF)患者血浆骨桥蛋白及心功能的影响.方法 60例CHF患者随机分为对照组30例和治疗组30例.两组患者常规给予吸氧、卧床休息、洋地黄、血管紧张素转换酶抑制剂、β受体阻滞剂、扩血管药、利尿剂等治疗.治疗组同时加用阿托伐他汀钙20mg/d,共治疗2个月.在治疗2个月后评价心功能(NHYA),心脏彩超测定左心室射血分数,检测血浆骨桥蛋白、血浆N末端脑利钠肽及C反应蛋白浓度.结果 治疗组血浆骨桥蛋白(1 062.68 ±130.63)ng/L]、血浆N末端脑利钠肽(609.00 ±62.39) ng/L]及C反应蛋白(5.84±0.70) mg/L]浓度低于对照组(1 609.94 ±201.87) ng/L、(922.33±108.68) ng/L、(8.90±0.86) mg/L],两组比较差异有统计学意义(Z=-1.981,t=2.766,Z=-2.092,P均<0.05).治疗组左心室射血分数(58.7±1.2)%高于对照组(52.8±1.6)%,两组比较差异有统计学意义(Z=-2.502,P<0.05).结论 阿托伐他汀可降低血浆骨桥蛋白浓度,减轻炎症反应,抑制心脏重构,从而对心力衰竭患者有益.

关 键 词:阿托伐他汀  血浆骨桥蛋白  血浆N末端脑利钠肽  C反应蛋白  心力衰竭

Effect of atorvastatin on osteopontin of patients with chronic heart failure
Shen Guibin,Zhang Lihua.Effect of atorvastatin on osteopontin of patients with chronic heart failure[J].Clinical Medicine of China,2014(4):376-378.
Authors:Shen Guibin  Zhang Lihua
Institution:Cardiology Department, The Seventh Ppeople's Hospital of Zhengzhou, Zhengzhou 450016, China
Abstract:Objective To investigate atorvastatin administration on osteopontin and cardiac function of patients with chronic heart failure(CHF).Methods Sixty CHF patients were randomly divided into control (30 cases) and atorvastatin groups (30 cases).Patients in control group were given regular treatment including conventional oxygen inhalation,digitalis,angiotensin converting enzyme inhibitors,β blockers,diuretics,vasodilator therapy.Patients in treatment group were given atorvastatin at dose of 20 mg/d for 2 months plus regular treatment.The NHYA cardiac function,echocardiography determination of left ventricular ejection fraction(LVEF) were recorded.The levels of plasma osteopontin,plasma N-terminal brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) were measured.Results The levels of plasma osteopontin,NT-proBNP and CRP in atorvastatin group were (1 062.68 ± 130.63) ng/L,(609.00 ±62.39) ng/L and ((5.84 ± 0.70) mg/L respectively,lower than those of control group ((1609.94 ± 201.87) ng/L,(922.33 ± 108.68) ng/L,(8.90 ± 0.86) mg/L),and the differences were statistically significant (Z =-1.981,t =2.766,Z =-2.092,P 〈0.05).LVEF in atorvastatin group was (58.7 ± 1.2)%,higher than that in control group ((52.8 ± 1.6) % ; P 〈 0.05).Conclusion Atorvastatin treatment can decrease plasma osteopontin density,alleviate the inflammatory response and inhibit cardiac remodeling in patients with heart failure,which was good for recovery of heart failure.
Keywords:Atorvastatin  Plasma osteopontin  Plasma N-terminal brain natriuretie peptide  C-reactive protein  Heart failure
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号